Zoetis Inc. (ETR:ZOE)

Germany flag Germany · Delayed Price · Currency is EUR
121.98
-3.30 (-2.63%)
Oct 10, 2025, 5:35 PM CET
-2.63%
Market Cap53.80B
Revenue (ttm)7.99B
Net Income (ttm)2.22B
Shares Outn/a
EPS (ttm)4.95
PE Ratio24.19
Forward PE21.55
Dividend1.75 (1.43%)
Ex-Dividend DateJul 18, 2025
Volume89
Average Volume299
Open123.98
Previous Close125.28
Day's Range121.98 - 123.98
52-Week Range119.54 - 179.58
Beta0.90
RSI41.07
Earnings DateNov 4, 2025

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]

Sector Healthcare
Founded 1950
Employees 13,800
Stock Exchange Deutsche Börse Xetra
Ticker Symbol ZOE
Full Company Profile

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Financial numbers in USD Financial Statements

News

Zoetis (ZTS): EMA Supports New Canine Osteoarthritis Treatment

Zoetis (ZTS): EMA Supports New Canine Osteoarthritis Treatment

1 day ago - GuruFocus

Zoetis (ZTS) Awaits EU Approval for Lenivia, an Osteoarthritis Treatment for Dogs

Zoetis (ZTS) Awaits EU Approval for Lenivia, an Osteoarthritis Treatment for Dogs

1 day ago - GuruFocus

Zoetis Receives Positive Opinion from CVMP for Lenivia (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing aut...

1 day ago - Wallstreet:Online

Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.

1 day ago - Business Wire

Daily Dividend Report: ZTS,DOW,R,PFE,LMT,NWN

The Board of Directors of Zoetis has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Comp...

1 day ago - Nasdaq

Zoetis Inc. (ZTS) Announces Fourth Quarter Dividend

Zoetis Inc. (ZTS) Announces Fourth Quarter Dividend

1 day ago - GuruFocus

Zoetis (ZTS) Maintains Quarterly Dividend, Sets Payment Date

Zoetis (ZTS) Maintains Quarterly Dividend, Sets Payment Date

2 days ago - GuruFocus

Zoetis Declares Fourth Quarter 2025 Dividend

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will ...

2 days ago - Business Wire

VHT, PFE, BMY, ZTS: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Health Care ETF (Symbol: VHT) where we have detected an appro...

5 days ago - Nasdaq

Top 50 High-Quality Dividend Growth Stocks For October 2025

I track a universe of 50 high-quality dividend growth stocks to identify opportune investments based on valuation and future return potential. As of October 2, 2025, 22 stocks offer attractive future ...

8 days ago - Seeking Alpha

Zoetis: A Solid Investment in the Growing Pet Medicine Market?

Could Zoetis be the next big opportunity in the pet medicine market? Tune in as our experts break down the company's strengths and weaknesses.

9 days ago - The Motley Fool

Zoetis: Much Bark, Little Bite - The Stock Remains Pricey

Zoetis Inc. is a global animal health leader with strong fundamentals and a robust innovation pipeline. Click here to read why ZTS stock is a Sell.

9 days ago - Seeking Alpha

Top 15 High-Growth Dividend Stocks For October 2025

The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown ...

9 days ago - Seeking Alpha

Zoetis (ZTS) Gains FDA Nod for Innovative Livestock Parasite Treatment

Zoetis (ZTS) Gains FDA Nod for Innovative Livestock Parasite Treatment

11 days ago - GuruFocus

Zoetis granted conditional approval of Dectomax-CA1 for parasitic infection in cattle

FDA conditionally approves Dectomax-CA1 to treat New World screwworm in cattle. Read more here.

11 days ago - Seeking Alpha

Zoetis Receives Conditional Approval for Dectomax-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

Zoetis Inc. today announced that Dectomax-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention an...

11 days ago - Wallstreet:Online

Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from ...

11 days ago - Business Wire

Zoetis (ZTS) Gains Conditional FDA Approval for Cattle Treatment

Zoetis (ZTS) Gains Conditional FDA Approval for Cattle Treatment

11 days ago - GuruFocus

ZTS Quantitative Stock Analysis - Warren Buffett

Below is Validea's guru fundamental report for ZOETIS INC (ZTS). Of the 22 guru strategies we follow, ZTS rates highest using our Patient Investor model based on the published strategy of Warren Buffe...

14 days ago - Nasdaq

Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing

Zoetis (ZTS) concluded the recent trading session at $143.5, signifying a +1.68% move from its prior day's close.

15 days ago - Nasdaq

Pet Pain For Investor Gain

ZTS is fundamentally a companion animal company, with the segment driving 68% of 2024 revenue and projected to reach 71% by 2030, fueled by aging pet demographics in the US. OA pain franchise, Librela...

15 days ago - Seeking Alpha

How Do Investors Really Feel About Zoetis?

Zoetis's (NYSE: ZTS) short interest as a percent of float has risen 17.45% since its last report. According to exchange reported data, there are now 7.76 million shares sold short , which is 1.75% of...

18 days ago - Benzinga

Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin...

18 days ago - Business Wire

Warren Buffett Detailed Fundamental Analysis - ZTS

Below is Validea's guru fundamental report for ZOETIS INC (ZTS). Of the 22 guru strategies we follow, ZTS rates highest using our Patient Investor model based on the published strategy of Warren Buffe...

19 days ago - Nasdaq